Q3 EPS Estimates for Haemonetics Lifted by Zacks Research

Haemonetics Co. (NYSE:HAE - Free Report) - Equities researchers at Zacks Research raised their Q3 2026 earnings estimates for shares of Haemonetics in a note issued to investors on Monday, February 17th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $1.33 per share for the quarter, up from their prior estimate of $1.31. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' Q3 2027 earnings at $1.48 EPS.

A number of other research analysts have also weighed in on HAE. Raymond James reiterated a "strong-buy" rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. JMP Securities cut their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. Needham & Company LLC reduced their target price on Haemonetics from $112.00 to $108.00 and set a "buy" rating for the company in a report on Friday, February 7th. Finally, Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price target for the stock from $95.00 to $68.00 in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $101.67.

Haemonetics Stock Performance

Shares of NYSE HAE traded down $0.47 during midday trading on Thursday, hitting $62.98. The company's stock had a trading volume of 986,273 shares, compared to its average volume of 1,030,576. The firm has a market capitalization of $3.16 billion, a price-to-earnings ratio of 24.79, a P/E/G ratio of 1.11 and a beta of 0.39. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a fifty day moving average price of $72.61 and a 200 day moving average price of $76.66. Haemonetics has a one year low of $58.80 and a one year high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.

Institutional Investors Weigh In On Haemonetics

Several hedge funds have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. purchased a new stake in shares of Haemonetics during the 4th quarter valued at $25,000. Covestor Ltd raised its position in Haemonetics by 146.8% during the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. bought a new stake in Haemonetics during the fourth quarter worth about $62,000. Nisa Investment Advisors LLC boosted its holdings in shares of Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 632 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its position in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.